AtriCure Inc. (NASDAQ:ATRC) CEO Michael H. Carrel sold 25,000 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $43.00, for a total transaction of $1,075,000.00. Following the completion of the sale, the chief executive officer now owns 651,490 shares of the company’s stock, valued at $28,014,070. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ ATRC opened at $43.84 on Friday. The company has a 50-day moving average price of $36.83 and a 200-day moving average price of $30.16. AtriCure Inc. has a 1 year low of $22.57 and a 1 year high of $44.32. The company has a current ratio of 3.11, a quick ratio of 2.49 and a debt-to-equity ratio of 0.29.
A number of research firms have commented on ATRC. BTIG Research began coverage on shares of AtriCure in a report on Thursday, February 6th. They issued a “buy” rating and a $42.00 price target for the company. BidaskClub upgraded shares of AtriCure from a “buy” rating to a “strong-buy” rating in a report on Friday, January 3rd. ValuEngine cut shares of AtriCure from a “buy” rating to a “hold” rating in a report on Tuesday, January 28th. Zacks Investment Research cut shares of AtriCure from a “hold” rating to a “sell” rating in a report on Tuesday, December 31st. Finally, Needham & Company LLC restated a “buy” rating and issued a $48.00 price target (up from $39.00) on shares of AtriCure in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $38.86.
AtriCure Company Profile
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Further Reading: Which market index is the best?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.